{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:56:05Z","timestamp":1791928565058,"version":"4.3.4"},"reference-count":93,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: The global health burden of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma, idiopathic pulmonary fibrosis (IPF), and acute respiratory distress syndrome (ARDS) affects billions of people and is associated with high levels of healthcare expenditure. Conventional therapies (bronchodilators and corticosteroids) provide symptomatic benefit but take no effect on disease progression, demonstrating the need to develop new therapies. Emerging therapies treat the underlying mechanisms of these chronic diseases, which provide symptomatic relief and benefit the underlying disease. Methods: This review assesses the evolution of therapeutic interventions for chronic lung diseases from a series of established inhaled combination therapies to biologics, gene therapy, and even AI-based stratification of therapies for patients. In addressing these issues, we review the mechanisms of action, evidence of efficacy, and clinical trial evidence, while discussing access issues affecting the implementation of these therapies and ethical issues in relation to their use. Results: The review highlights recent developments in treatment approaches, such as gene therapies aimed at cystic fibrosis mutations, advanced drug delivery pathways for more accurate targeting, and stem cell-based therapies designed to replace damaged lung tissue. These developments have the potential to improve outcomes for chronic lung diseases, but the challenges, including a lack of access, adequate patient selection, and long-term safety, need to be addressed. Conclusions: New therapies offer tremendous potential, but their transition from laboratory to clinic still face numerous barriers including access, regulation, and a need for personalized therapy approaches. The review indicates that future research should develop strategies to reduce barriers to access, improve distribution, and improve clinical guidelines to successfully implement these new therapies.<\/jats:p>","DOI":"10.3390\/jcm14093118","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T09:16:12Z","timestamp":1746090972000},"page":"3118","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Advances in Therapeutics for Chronic Lung Diseases: From Standard Therapies to Emerging Breakthroughs"],"prefix":"10.3390","volume":"14","author":[{"given":"Kyle D.","family":"Brewer","sequence":"first","affiliation":[{"name":"Advanced Drug Delivery and Regenerative Biomaterials Laboratory, Cardiovascular Institute, Stanford, CA 94304, USA"},{"name":"Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niki V.","family":"Santo","sequence":"additional","affiliation":[{"name":"Swaza, Inc., Mountain View, CA 94043, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankur","family":"Samanta","sequence":"additional","affiliation":[{"name":"Swaza, Inc., Mountain View, CA 94043, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronjon","family":"Nag","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artem A.","family":"Trotsyuk","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayakumar","family":"Rajadas","sequence":"additional","affiliation":[{"name":"Advanced Drug Delivery and Regenerative Biomaterials Laboratory, Cardiovascular Institute, Stanford, CA 94304, USA"},{"name":"Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"ref_1","unstructured":"GBD Chronic Respiratory Disease Collaborators (2020). Prevalence and attributable health burden of chronic respiratory diseases, 1990\u20132017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir. Med., 8, 585\u2013596."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"100623","DOI":"10.1016\/j.waojou.2021.100623","article-title":"Prevalence of asthma symptoms and associated risk factors among adults in Saudi Arabia: A national survey from Global Asthma Network Phase I","volume":"15","author":"Alomary","year":"2022","journal-title":"World Allergy Organ. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1750-1172-3-8","article-title":"Idiopathic pulmonary fibrosis","volume":"3","author":"Meltzer","year":"2008","journal-title":"Orphanet. J. Rare. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"104166","DOI":"10.1016\/j.lpm.2023.104166","article-title":"Idiopathic pulmonary fibrosis","volume":"52","author":"Koudstaal","year":"2023","journal-title":"Presse. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41572-019-0069-0","article-title":"Acute respiratory distress syndrome","volume":"5","author":"Matthay","year":"2019","journal-title":"Nat. Rev. Dis. Primers."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1900491","DOI":"10.1183\/13993003.00491-2019","article-title":"Asthma progression and mortality: The role of inhaled corticosteroids","volume":"54","author":"Fabbri","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e1138","DOI":"10.1016\/S2214-109X(23)00304-2","article-title":"COPD generates substantial cost for health systems","volume":"11","author":"Agarwal","year":"2023","journal-title":"Lancet Glob. Health."},{"key":"ref_8","first-page":"7","article-title":"Guiding Principles for the Use of Nebulized Long-Acting Beta2-Agonists in Patients with COPD: An Expert Panel Consensus","volume":"4","author":"Wise","year":"2016","journal-title":"Chronic. Obstr. Pulm. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41533-023-00347-6","article-title":"Rational use of inhaled corticosteroids for the treatment of COPD","volume":"33","author":"Quint","year":"2023","journal-title":"NPJ Prim. Care Respir. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1164\/rccm.201810-1944CI","article-title":"Role of Biologics in Asthma","volume":"199","author":"McGregor","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Plichta, J., Kuna, P., and Panek, M. (2023). Biologic drugs in the treatment of chronic inflammatory pulmonary diseases: Recent developments and future perspectives. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1207641"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Karampitsakos, T., Vraka, A., Bouros, D., Liossis, S.N., and Tzouvelekis, A. (2019). Biologic Treatments in Interstitial Lung Diseases. Front. Med., 6.","DOI":"10.3389\/fmed.2019.00041"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/MCP.0000000000000552","article-title":"Wildfire smoke exposure under climate change: Impact on respiratory health of affected communities","volume":"25","author":"Reid","year":"2019","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1183\/09031936.01.17510240","article-title":"Urban air pollution and chronic obstructive pulmonary disease: A review","volume":"17","author":"Sunyer","year":"2001","journal-title":"Eur. Respir. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/s12964-024-01713-8","article-title":"CRISPR\/Cas9 gene editing: A novel strategy for fighting drug resistance in respiratory disorders","volume":"22","author":"Hussen","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41587-024-02143-0","article-title":"A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models","volume":"43","author":"Ren","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S2213-2600(23)00159-5","article-title":"Respiratory sequelae of COVID-19: Pulmonary and extrapulmonary origins, and approaches to clinical care and rehabilitation","volume":"11","author":"Singh","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e002528","DOI":"10.1136\/bmjresp-2024-002528","article-title":"Risk of long covid in patients with pre-existing chronic respiratory diseases: A systematic review and meta-analysis","volume":"12","author":"Terry","year":"2025","journal-title":"BMJ Open Respir. Res."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Lai, Y.J., Liu, S.H., Manachevakul, S., Lee, T.A., Kuo, C.T., and Bello, D. (2023). Biomarkers in long COVID-19: A systematic review. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1085988"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"100849","DOI":"10.1016\/S2666-5247(24)00055-7","article-title":"Blood transcriptomic analyses reveal persistent SARS-CoV-2 RNA and candidate biomarkers in post-COVID-19 condition","volume":"5","author":"Menezes","year":"2024","journal-title":"Lancet Microbe."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Plotnick, L.H., and Ducharme, F.M. (2000). Combined inhaled anticholinergic agents and beta-2-agonists for initial treatment of acute asthma in children. Cochrane. Database. Syst. Rev., CD000060.","DOI":"10.1002\/14651858.CD000060"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.coph.2020.05.002","article-title":"Phosphodiesterase isoforms and cAMP compartments in the development of new therapies for obstructive pulmonary diseases","volume":"51","author":"Schmidt","year":"2020","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.21037\/jtd-23-1781","article-title":"A narrative review of theophylline: Is there still a place for an old friend?","volume":"16","author":"Scurek","year":"2024","journal-title":"J. Thorac. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.rmed.2005.11.020","article-title":"Systemic side effects of inhaled corticosteroids in patients with asthma","volume":"100","author":"Dahl","year":"2006","journal-title":"Respir. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.2147\/COPD.S185975","article-title":"Triple therapy (ICS\/LABA\/LAMA) in COPD: Time for a reappraisal","volume":"13","author":"Vanfleteren","year":"2018","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2147\/PPA.S395327","article-title":"Factors Affecting Patient Adherence to Inhalation Therapy: An Application of SEIPS Model 2.0","volume":"17","author":"Ma","year":"2023","journal-title":"Patient Prefer. Adherence."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2147\/COPD.S3483","article-title":"Treatment of mild chronic obstructive pulmonary disease","volume":"3","author":"Chee","year":"2008","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"ref_28","first-page":"e55109","article-title":"Beneath the Surface: Exploring Hidden Threats of Long-Term Corticosteroid Therapy to Bone Density","volume":"16","author":"Alfaedi","year":"2024","journal-title":"Cureus"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/cea.13885","article-title":"Treating severe asthma: Targeting the IL-5 pathway","volume":"51","author":"Principe","year":"2021","journal-title":"Clin. Exp. Allergy"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1007\/s40265-023-01950-0","article-title":"Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis","volume":"83","author":"Bonella","year":"2023","journal-title":"Drugs"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jaip.2024.01.023","article-title":"Phenotyping of Severe Asthma in the Era of Broad-Acting Anti-Asthma Biologics","volume":"12","author":"Bourdin","year":"2024","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_32","first-page":"RA300\u20135","article-title":"Non-pharmacological treatment for chronic obstructive pulmonary disease","volume":"9","author":"Clini","year":"2003","journal-title":"Med. Sci. Monit."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"184","DOI":"10.34197\/ats-scholar.2023-0069RE","article-title":"Current Landscape and Future Directions of Patient Education in Adults with Interstitial Lung Disease","volume":"5","author":"Savvaides","year":"2023","journal-title":"ATS Sch."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000488291","article-title":"Bronchial Thermoplasty in Severe Asthma: Best Practice Recommendations from an Expert Panel","volume":"95","author":"Bonta","year":"2018","journal-title":"Respiration"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jaip.2018.08.017","article-title":"Bronchial Thermoplasty: A Decade of Experience: State of the Art","volume":"7","author":"Tan","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1164\/rccm.202008-3173ED","article-title":"One Step Forward, Two Steps Back: Bronchial Thermoplasty for Asthma","volume":"203","author":"Krishnan","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.2147\/COPD.S267409","article-title":"AIRFLOW-2 Trial Study Group. Two-Year Outcomes for the Double-Blind, Randomized, Sham-Controlled Study of Targeted Lung Denervation in Patients with Moderate to Severe COPD: AIRFLOW-2","volume":"15","author":"Valipour","year":"2020","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12931-020-01383-3","article-title":"Targeted lung denervation in sheep: Durability of denervation and long-term histologic effects on bronchial wall and peribronchial structures","volume":"21","author":"Mayse","year":"2020","journal-title":"Respir. Res."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Slebos, D.J., Degano, B., Valipour, A., Shah, P.L., Desl\u00e9e, G., and Sciurba, F.C. (2020). AIRFLOW-3 Trial Study Group. Design for a multicenter, randomized, sham-controlled study to evaluate safety and efficacy after treatment with the Nuvaira\u00ae lung denervation system in subjects with chronic obstructive pulmonary disease (AIRFLOW-3). BMC Pulm. Med., 20.","DOI":"10.1186\/s12890-020-1058-5"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"A6465","DOI":"10.1016\/j.chest.2024.07.078","article-title":"Targeted lung denervation in copd: Outcomes from the airflow-3 open label cohort","volume":"166","author":"Ghattas","year":"2024","journal-title":"Chest"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/15412555.2011.560132","article-title":"Neuromodulatory effect of endogenous opioids on the intensity and unpleasantness of breathlessness during resistive load breathing in COPD","volume":"8","author":"Gifford","year":"2011","journal-title":"J. Chronic Obstr. Pulm. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Tharu, N.S., Suthar, A., Gerasimenko, Y., Castillo, C., Ng, A., and Ovechkin, A. (2024). Noninvasive Electrical Modalities to Alleviate Respiratory Deficits Following Spinal Cord Injury. Life, 14.","DOI":"10.3390\/life14121657"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1378\/chest.09-2555","article-title":"Oxygen therapy for patients with COPD: Current evidence and the long-term oxygen treatment trial","volume":"138","author":"Stoller","year":"2010","journal-title":"Chest"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13063-018-2492-z","article-title":"High-flow nasal oxygen vs. standard oxygen therapy in immunocompromised patients with acute respiratory failure: Study protocol for a randomized controlled trial","volume":"19","author":"Azoulay","year":"2018","journal-title":"Trials"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1183\/09059180.00000513","article-title":"Practical recommendations for exercise training in patients with COPD","volume":"22","author":"Gloeckl","year":"2013","journal-title":"Eur. Respir. Rev."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1164\/rccm.202306-1066ST","article-title":"Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline","volume":"208","author":"Rochester","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"103017","DOI":"10.1016\/j.eclinm.2024.103017","article-title":"Beyond bronchial thermoplasty-where to now?","volume":"79","author":"Noble","year":"2024","journal-title":"EClinicalMedicine"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"240008","DOI":"10.1183\/16000617.0008-2024","article-title":"Neuroimmune recognition and regulation in the respiratory system","volume":"33","author":"Chen","year":"2024","journal-title":"Eur. Respir. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1152\/physiol.00030.2018","article-title":"Electroceutical Targeting of the Autonomic Nervous System","volume":"34","author":"Horn","year":"2019","journal-title":"Physiology"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Konkimalla, A., Tata, A., and Tata, P.R. (2022). Lung Regeneration: Cells, Models, and Mechanisms. Cold Spring Harb. Perspect. Biol., 14.","DOI":"10.1101\/cshperspect.a040873"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1146\/annurev-physiol-041520-092904","article-title":"Epithelial Stem and Progenitor Cells in Lung Repair and Regeneration","volume":"83","author":"Alysandratos","year":"2021","journal-title":"Annu. Rev. Physiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1146\/annurev-pathmechdis-031621-024344","article-title":"After the Storm: Regeneration, Repair, and Reestablishment of Homeostasis Between the Alveolar Epithelium and Innate Immune System Following Viral Lung Injury","volume":"18","author":"Planer","year":"2023","journal-title":"Annu. Rev. Pathol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.pccm.2022.12.002","article-title":"Pulmonary fibrosis: A short- or long-term sequelae of severe COVID-19?","volume":"1","author":"Zheng","year":"2023","journal-title":"Chin. Med. J. Pulm. Crit. Care Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"C675","DOI":"10.1152\/ajpcell.00036.2020","article-title":"Stem cells and lung regeneration","volume":"319","author":"Parekh","year":"2020","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e23612","DOI":"10.1096\/fj.202400088R","article-title":"Repair and regeneration of the alveolar epithelium in lung injury","volume":"38","author":"Wang","year":"2024","journal-title":"FASEB J."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Leszczy\u0144ska, K., Jakubczyk, D., and G\u00f3rska, S. (2022). The NLRP3 inflammasome as a new target in respiratory disorders treatment. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1006654"},{"key":"ref_57","first-page":"97","article-title":"Inhibitors of the Autotaxin-Lysophosphatidic Acid Axis and Their Potential in the Treatment of Interstitial Lung Disease: Current Perspectives","volume":"12","author":"Zulfikar","year":"2020","journal-title":"Clin. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"00447","DOI":"10.1183\/23120541.00447-2020","article-title":"First clinical trials of the inhaled epithelial sodium channel inhibitor BI 1265162 in healthy volunteers","volume":"7","author":"Mackie","year":"2021","journal-title":"ERJ Open. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.cell.2025.01.029","article-title":"HypoxyStat, a small-molecule form of hypoxia therapy that increases oxygen-hemoglobin affinity","volume":"188","author":"Blume","year":"2025","journal-title":"Cell"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","article-title":"Why 90% of clinical drug development fails and how to improve it?","volume":"12","author":"Sun","year":"2022","journal-title":"Acta. Pharm. Sin. B."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"31813","DOI":"10.3402\/ecrj.v3.31813","article-title":"Severe asthma: Anti-IgE or anti-IL-5?","volume":"3","author":"Papathanassiou","year":"2016","journal-title":"Eur. Clin. Respir. J."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1172\/JCI112506","article-title":"Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates","volume":"77","author":"Stevens","year":"1986","journal-title":"J. Clin. Investig."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e764","DOI":"10.1016\/S2665-9913(20)30341-6","article-title":"Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): An exploratory, open-label, phase 2 randomised controlled trial","volume":"2","author":"Vlaar","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.addr.2018.01.020","article-title":"Integrins in wound healing, fibrosis and tumor stroma: High potential targets for therapeutics and drug delivery","volume":"129","author":"Schnittert","year":"2018","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Chung, C., Kudchodkar, S.B., Chung, C.N., Park, Y.K., Xu, Z., Pardi, N., Abdel-Mohsen, M., and Muthumani, K. (2023). Expanding the Reach of Monoclonal Antibodies: A Review of Synthetic Nucleic Acid Delivery in Immunotherapy. Antibodies, 12.","DOI":"10.3390\/antib12030046"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Mosch, R., and Guchelaar, H.J. (2022). Immunogenicity of Monoclonal Antibodies and the Potential Use of HLA Haplotypes to Predict Vulnerable Patients. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.885672"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"149257","DOI":"10.1016\/j.gene.2025.149257","article-title":"Unlocking the potential of CRISPR-Cas9 for cystic fibrosis: A systematic literature review","volume":"942","author":"Harris","year":"2025","journal-title":"Gene"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"9471","DOI":"10.1038\/s41467-024-53914-x","article-title":"Charge-assisted stabilization of lipid nanoparticles enables inhaled mRNA delivery for mucosal vaccination","volume":"15","author":"Liu","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10555-017-9717-6","article-title":"RNA interference-based therapy and its delivery systems","volume":"37","author":"Chen","year":"2018","journal-title":"Cancer Metastasis Rev."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1084\/jem.20100035","article-title":"miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis","volume":"207","author":"Liu","year":"2010","journal-title":"J. Exp. Med."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Zhou, Z., Xie, Y., Wei, Q., Zhang, X., and Xu, Z. (2024). Revisiting the role of MicroRNAs in the pathogenesis of idiopathic pulmonary fibrosis. Front. Cell Dev. Biol., 12.","DOI":"10.3389\/fcell.2024.1470875"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug delivery systems for RNA therapeutics","volume":"23","author":"Paunovska","year":"2022","journal-title":"Nat. Rev. Genet."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.2147\/JIR.S372046","article-title":"Therapeutic Benefits of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome: Potential Mechanisms and Challenges","volume":"15","author":"Cao","year":"2022","journal-title":"J. Inflamm. Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1007\/s13346-021-00954-1","article-title":"Nanoparticle-mediated pulmonary drug delivery: State of the art towards efficient treatment of recalcitrant respiratory tract bacterial infections","volume":"11","author":"Huang","year":"2021","journal-title":"Drug. Deliv. Transl. Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/j.athoracsur.2021.07.045","article-title":"Extracorporeal Membrane Oxygenation and Perfluorocarbon in a Therapy Refractory Case of Acute Respiratory Distress Syndrome","volume":"113","author":"Voelker","year":"2022","journal-title":"Ann. Thorac. Surg."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S2213-2600(22)00492-1","article-title":"DESTINATION study investigators. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): A randomised, placebo-controlled extension study","volume":"11","author":"Wechsler","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.drudis.2022.04.009","article-title":"Multimodal molecular imaging in drug discovery and development","volume":"27","author":"Vermeulen","year":"2022","journal-title":"Drug. Discov. Today"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2147\/PPA.S385857","article-title":"Advancing Digital Solutions to Overcome Longstanding Barriers in Asthma and COPD Management","volume":"17","author":"Bakerly","year":"2023","journal-title":"Patient Prefer. Adherence"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Wilkinson, I., Anderson, S., Fry, J., Julien, L.A., Neville, D., Qureshi, O., Watts, G., and Hale, G. (2021). Fc-engineered antibodies with immune effector functions completely abolished. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0260954"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4046\/trd.2021.0179","article-title":"Prevalence and Impact of Comorbidities in Individuals with Chronic Obstructive Pulmonary Disease: A Systematic Review","volume":"85","author":"Santos","year":"2022","journal-title":"Tuberc. Respir. Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"7929","DOI":"10.1021\/acs.analchem.9b01800","article-title":"Salivary Thiocyanate as a Biomarker of Cystic Fibrosis Transmembrane Regulator Function","volume":"91","author":"Malkovskiy","year":"2019","journal-title":"Anal. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"107720","DOI":"10.1016\/j.pec.2023.107720","article-title":"Biomarker testing communication, familiarity, and informational needs among people living with breast, colorectal, and lung cancer","volume":"112","author":"Fortune","year":"2023","journal-title":"Patient Educ. Couns."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"023901","DOI":"10.1118\/1.4859315","article-title":"Comparison of patient specific dose metrics between chest radiography, tomosynthesis, and CT for adult patients of wide ranging body habitus","volume":"41","author":"Zhang","year":"2014","journal-title":"Med. Phys."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.carj.2015.07.002","article-title":"Radiation Dose Survey for Common Computed Tomography Exams: 2013 British Columbia Results","volume":"67","author":"Thakur","year":"2016","journal-title":"Can. Assoc. Radiol. J."},{"key":"ref_86","first-page":"674","article-title":"Gene therapy may not be as expensive as people think: Challenges in assessing the value of single and short-term therapies","volume":"27","author":"Garrison","year":"2021","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"101654","DOI":"10.1016\/j.adro.2024.101654","article-title":"The Burden of Insurance Prior Authorization on Cancer Care: A Review of Evidence from Radiation Oncology","volume":"10","author":"Gracie","year":"2024","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Hussain, T., Ullah, S., Fern\u00e1ndez-Garc\u00eda, R., and Gil, I. (2023). Wearable Sensors for Respiration Monitoring: A Review. Sensors, 23.","DOI":"10.20944\/preprints202308.0876.v1"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"230189","DOI":"10.1183\/20734735.0189-2023","article-title":"Artificial intelligence in respiratory care: Perspectives on critical opportunities and challenges","volume":"20","author":"Drummond","year":"2024","journal-title":"Breathe"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Tsai, C.H., Eghdam, A., Davoody, N., Wright, G., Flowerday, S., and Koch, S. (2020). Effects of Electronic Health Record Implementation and Barriers to Adoption and Use: A Scoping Review and Qualitative Analysis of the Content. Life, 10.","DOI":"10.3390\/life10120327"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.cjca.2024.02.014","article-title":"Challenges in Promoting Health Equity and Reducing Disparities in Access Across New and Established Technologies","volume":"40","author":"Hoagland","year":"2024","journal-title":"Can. J. Cardiol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40258-024-00937-6","article-title":"Cost-Effective and Sustainable Drug Use in Hospitals: A Systematic and Practice-Based Approach","volume":"23","author":"Zietse","year":"2025","journal-title":"Appl. Health Econ. Health Policy"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4103\/atm.atm_192_23","article-title":"Artificial intelligence in respiratory care: Current scenario and future perspective","volume":"19","author":"Alanazi","year":"2024","journal-title":"Ann. Thorac. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/9\/3118\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:25:16Z","timestamp":1760030716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/9\/3118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":93,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["jcm14093118"],"URL":"https:\/\/doi.org\/10.3390\/jcm14093118","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]}}}